πŸ‡ΊπŸ‡Έ FDA
Patent

US 12110343

Anti-plasma kallikrein antibodies

granted A61PA61P29/00A61P31/04

Quick answer

US patent 12110343 (Anti-plasma kallikrein antibodies) held by Takeda Pharmaceutical Company Limited expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P29/00, A61P31/04, A61P35/00, A61P43/00